<DOC>
	<DOC>NCT01437670</DOC>
	<brief_summary>A prospective, multicenter, observation study to estimate the dry mouth in OAB patients with solifenacin</brief_summary>
	<brief_title>Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin</brief_title>
	<detailed_description>To estimate the dry mouth and their impact on the efficacy of the drug in overactive bladder patients with solifenacin</detailed_description>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>1) male or female patients with 20 years of age or older 2) clinical history of OAB for at least 3 months prior to visit 2 3) more than 3 in total score and 2 in Q 3 index from OABSS questionnaire 1) In clinical trial, female with pregnant, intent to become pregnant or breastfeeding 2)postvoided residual urine volume &gt; 150ml 3) a history of catheterization due to acute urinary retention 4) a history of pelvic surgery within 6 months 5) 6) 7) a history of neurovascular disease such as Parkinson's disease, cerebral vascular disease, spinal injury or multiple sclerosis 8)patients with indwelling catheter or intermittent catheterization 9) active or recurrent (&gt;3 episodes per year) urinary tract infection 10) the use of the following medication at least 2 weeks anticholinergics Tricyclic antidepressants,antiepilepsy drug, antiParkinson's disease drug, antiarrythmia drug type I Chlorpromazine, Thioridazine, Piperazine MAO inhibitor 11) Patient is currently taking or has taken within the past 4 weeks alphablocker for the treatment of benign prostatic hypertrophy 12) Patient is currently taking or has taken within the past 8 weeks 5ARI or estrogen medication 13) Patient is currently using or has used medications with known activities as inhibitors or inducers of cytochrome P4503A4 (CYP3A4)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>